XNK Therapeutics gets abstract on ACP-001 selected for presentation at EHA2022 ...Middle East

STOCKHOLM, May 2, 2022 /PRNewswire/ -- XNK Therapeutics AB ("XNK") today announced that an abstract on the long-term follow-up of the Phase I/II clinical trial study ACP-001 with its leading candidate drug has been selected for a presentation at European Hematology Association's hybrid...

Hence then, the article about xnk therapeutics gets abstract on acp 001 selected for presentation at eha2022 was published today ( Monday 02/05/2022 - 03:15 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( XNK Therapeutics gets abstract on ACP-001 selected for presentation at EHA2022 )

Also on site :

• Ukraine will try “to get some concessions” from Trump at meeting
• Numbrix 9 - December 28
• Getting hired in 2026 is all about your ‘microcredentials’ says CEO of $1.3 billion learning platform—this is what he tells Gen Z to focus on